Peter Hecht, Cyclerion Therapeutics CEO

Hard pressed for cash, Cy­cle­ri­on looks for help fund­ing rare dis­ease drug

Cy­cle­ri­on Ther­a­peu­tics may have the de­sign of a Phase IIb study ready to go, but it’s scram­bling for a way to fund it.

The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.